A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Venetoclax (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 25 Jun 2017 Safety and efficacy results (n=66) presented at the 22nd Congress of the European Haematology Association.
    • 10 Jun 2017 Biomarkers information updated
    • 05 Apr 2017 Results of correlative biomarker analyses (n=66) presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top